Medtronic anticipates the separation of its diabetes business unit into a wholly separate entity to complete within 18 months ...

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes ...

Medtronic PLC (MDT) reports robust organic growth and strategic initiatives, including a Diabetes business spin-off, to ...

Medtronic, a healthcare technology company based in Ireland, plans to separate its diabetes business into a standalone, publicly traded company by the end of 2026.  The company announced the move May ...

Medtronic (NYSE: MDT) announced some personnel moves, including the departure of a longtime leader across multiple business ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of ...

Medtronic (NYSE: MDT) announced today that it received CE mark for several expanded indications for its Prevail balloon ...

Q4 2025 Earnings Call Transcript May 21, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.62, expectations ...

With 7% top-line growth and 8% bottom-line growth across the majority of its divisions, Abbott Labs reported a solid ...

Integration of Abbott's glucose-ketone sensor with the twiist™ AID System aims to enhance early identification of rising ketones to detect the risk of diabetic ketoacidosis (DKA)1 MANCHESTER, N.H., ...